M&A Deal Summary

Charles River Laboratories International Acquires Vigene Biosciences

On May 17, 2021, Charles River Laboratories International acquired life science company Vigene Biosciences for 293M USD

Acquisition Highlights
  • This is Charles River Laboratories International’s 26th transaction in the Life Science sector.
  • This is Charles River Laboratories International’s 7th largest (disclosed) transaction.
  • This is Charles River Laboratories International’s 18th transaction in the United States.
  • This is Charles River Laboratories International’s 1st transaction in Maryland.

M&A Deal Summary
Date 2021-05-17
Target Vigene Biosciences
Sector Life Science
Buyer(s) Charles River Laboratories International
Deal Type Add-on Acquisition
Deal Value 293M USD
Advisor(s) Baird (Financial)
Shulman Rogers
Sheppard Mullin (Legal)

Target

Vigene Biosciences

Rockville, Maryland, United States
Vigene Biosciences is a viral vector based gene delivery for both life science research, gene therapy and cell therapy purposes. Vigene offers AAV, lentivirus, and adenovirus based products and custom services. Vigene Biosciences was founded in 2012 and is based in Rockville, Maryland.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Charles River Laboratories International

Wilmington, Massachusetts, United States
Category Company
Founded 1947
Sector Life Science
Employees20,400
Revenue 4.1B USD (2023)
DESCRIPTION

Charles River Laboratories International is a provider of essential products and contract services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Charles River Laboratories International was incorporated in 1947 and is based in Wilmington, Massachusetts.

DEAL STATS #
Overall 29 of 31
Sector (Life Science) 26 of 28
Type (Add-on Acquisition) 24 of 26
State (Maryland) 1 of 1
Country (United States) 18 of 20
Year (2021) 4 of 4
Size (of disclosed) 7 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-31 Retrogenix

Chinley, United Kingdom

Retrogenix is an early-stage contract research organization (CRO) providing specialized bioanalytical services utilizing its proprietary cell microarray technology. Retrogenix is based in Chinley, United Kingdom.

Buy £35M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-06 Explora BioLabs

San Diego, California, United States

Explora BioLabs provides vivarium and contract research services to companies ranging from early-stage biotechs to large pharma. Explora's Ph.D.-backed suite of Vivarium-as-a-Service solutions provides the vivarium-related resources that biotechnology organizations need to begin in vivo studies in as little as two weeks. Whether operating out of their own vivarium or utilizing Explora's growing network of nationwide facilities, clients have access to Explora's experienced vivarium management, facility design, rodent housing and caging equipment, supply chain management, regulatory compliance, and veterinary oversight. For clients whose research programs or internal expertise is at capacity, Explora offers preclinical contract research staff and services to support the design and execution of preclinical studies for oncology, metabolic diseases, pharmacokinetics, non-GLP toxicology, pain, and a variety of other common therapeutic areas. Explora BioLabs is based in San Diego, California.

Buy -
Mergr

Product

Company

Legal